Loading
MK-3475A / Calderasib / Non Small Cell Lung Cancer · Phase 3 Trial
ClinicalTrials.gov · August 17, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a Phase 3 registration record for a randomized controlled trial comparing calderasib plus MK-3475A versus placebo plus MK-3475A in adjuvant treatment of completely resected KRAS G12C-mutant NSCLC. No results are posted in this registry record; the study is currently recruiting.
Phase 3, Interventional, Randomized, Parallel, Triple masking, Treatment purpose. Non-small Cell Lung Cancer; age from 18 Years. Intervention: Calderasib + MK-3475A. Compared with: Placebo + MK-3475A — Active Comparator. n = 400. 86 sites across 15 countries.
This is a Phase 3 registration record for a randomized controlled trial comparing calderasib plus MK-3475A versus placebo plus MK-3475A in adjuvant treatment of completely resected KRAS G12C-mutant NSCLC. No results are posted in this registry record; the study is currently recruiting.
Registry record contains no efficacy, safety, or outcome data; study is still recruiting.
This trial addresses an unmet need in adjuvant therapy for a molecularly defined subset of resected NSCLC. Results are not yet available; clinicians should monitor for publication of primary outcome data.
Phase 3 randomized controlled trial currently recruiting with no results reported; registry record describes planned design and endpoints only.
As stated by the source record.
Quoted from the source exactly as published.
This trial addresses an unmet need in adjuvant therapy for a molecularly defined subset of resected NSCLC. Results are not yet available; clinicians should monitor for publication of primary outcome data.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT07431827). This is a study registration, not published results. Lead sponsor: Merck Sharp & Dohme LLC. Recruitment status: RECRUITING. Phase: PHASE3. Study type: INTERVENTIONAL. Enrollment: 400 participants (ESTIMATED). Conditions: Non-small Cell Lung Cancer. Interventions: DRUG: Calderasib; BIOLOGICAL: MK-3475A; DRUG: Placebo. Primary outcome measures: Disease-free Survival (DFS) , Up to ~11 years. Brief summary: This is a phase 3, randomized, double-blind study of adjuvant calderasib plus subcutaneous pembrolizumab and berahyaluronidase alfa (MK-3475A) versus adjuvant placebo plus MK-3475a in participants with completely resected stage IIA-IIIB (N2), KRAS G12C-mutant non-small cell lung cancer following receipt of either neoadjuvant pembrolizumab plus chemotherapy or adjuvant chemotherapy. The primary goal of the study is to compare adjuvant calderasib plus MK-3475A to adjuvant placebo plus MK-3475A with respect to disease-free survival (DFS) as assessed by the investigator.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.